The leader in needle-free auto-injection for life-threatening emergency situations

CROSSJECT is a specialty pharmaceutical company revolutionizing the delivery of rapid-acting emergency medications through ZENEO®, its safe and reliable needle-free auto-injector designed for critical situations.

Epileptic seizure

Globally, approximately 65 million people live with epilepsy, of whom around 40% experience refractory seizures that remain uncontrolled despite chronic treatments.

Adrenal crisis

**Acute Adrenal Crisis (AAC)** is a potentially life-threatening condition classified as a rare disease, with a prevalence of approximately 5 people per 10,000 in the United States and Europe.

Allergic shock

Anaphylaxis is a severe and potentially life-threatening allergic reaction that requires immediate emergency treatment to prevent fatal outcomes.

Epileptic seizure

**Acute Adrenal Crisis (AAC)** is a potentially life-threatening condition classified as a rare disease, with a prevalence of approximately 5 people per 10,000 in the United States and Europe.

Adrenal crisis

Globally, approximately 65 million people live with epilepsy, of whom around 40% experience refractory seizures that remain uncontrolled despite chronic treatments.

Allergic shock

Anaphylaxis is a severe and potentially life-threatening allergic reaction that requires immediate emergency treatment to prevent fatal outcomes.

ZENEO® is a needle-free, pre-filled, single-use auto-injector

NEEDLE-FREE, FAST, RELIABLE, SAFE, AND VERY EASY TO USE

ZENEO®
Technology

The ZENEO® technology is the foundation of our innovative solutions

ABOUT CROSSJECT

CROSSJECT is revolutionizing drug delivery

INVESTORS

Press Releases

Our News

Newsletter

Send us a message